Serine protease inhibitors such as those active against acetyl cholinesterase (AChE) provide considerable protection against topical vesication caused by the blistering agent, sulfur mustard. At the same time, non-steroidal anti-inflammatory drugs (NSAIDs) have also been found to significantly diminish the pain and inflammation as long as applied in the early stages of exposure. A number of irreversible enzyme inhibitors are known as well as a wide class of optional NSAIDs. Our laboratory has discovered a unique class of substituted aryl carbonates of type I, and II which contain lipophilic fragments (-O-CH2-CH2-CMe3) and (-O-CH2-CH2-SiMe3) that are isosteres of natural choline. These inhibit AChE by a suicide approach. Building on these AChE inhibitors, we have developed a synthesis of bi-functional pharmaceuticals which not only possess site-specificity for AChE but also release an NSAID in the target area in expectation of a dual prophylactic/therapeutic approach to sulfur mustard exposure. Details on the syntheses and inhibition assays of substituted aryl carbonates of type I, and II will be presented.